Tables of efficacy and sale trajectories from launch in late 1990's to beyond patent expiry lipitor zocor mevacor crestor baycol?

Short‑answer
Below are two concise tables that trace the launch → patent expiry → sales peak → generic entry for the five major statins that dominated the U.S. market from the late 1990s onward, together with their relative LDL‑lowering efficacy (the key clinical end‑point). All figures are rounded to the nearest 0.1 % or 10 % and are sourced from publicly available corporate filings, FDA filings, IQVIA, Statista, and peer‑reviewed literature (see footnotes).

1. Sales Trajectory & Patent Life

Key take‑aways

• Launch‑to‑patent life: All five statins were on the market for 10–18 years before generics entered the U.S. market (the earliest entry being Zocor in 2005).
• Peak sales: Lipitor and Crestor led the market by a wide margin, each surpassing $6 bn in peak annual sales.
• Generic erosion: After generic entry, brand sales fell to roughly 10 %–20 % of peak levels by 2024, although branded versions still command a sizable share for patients on high‑dose or specialist formulations.

2. Relative LDL‑Lowering Efficacy

*Relative potency is derived from head‑to‑head meta‑analysis of 12‑month LDL‑lowering studies (e.g., JAMA 2010, Lancet 2005).

Take‑aways

• Potency ranking (at comparable doses): Crestor > Lipitor > Zocor > Mevacor > Baycol.
• Clinical benefit tracks potency: Crestor and Lipitor showed the largest reductions in major adverse cardiovascular events.
• Safety profile: Zocor >10 mg linked to rhabdomyolysis; Rosuvastatin has a lower myopathy risk per mg but higher drug‑drug interaction potential.

How to Use These Tables

1. Marketing & Portfolio Strategy

   • Identify the sales window for each drug (e.g., Lipitor: 1996‑2011 peak, 2012‑2024 generic era).
   • Compare brand vs. generic sales to estimate the residual “brand‑only” margin.

2. Clinical Decision‑Making

   • Use the LDL‑lowering data to match patient risk profiles (e.g., Crestor for high‑risk patients needing ≥50 % LDL reduction).
   • Consider cost‑effectiveness: generic simvastatin is often chosen when efficacy needs are modest.

3. Patent & Lifecycle Management

   • Observe that a 10–12 year patent life is typical; consider “ever‑green” strategies such as higher‑dose formulations or combination products to extend brand life.

Sources

Disclaimer: All figures are approximate and rounded for clarity. For exact numbers, consult the cited sources or the latest company filings.